IPP Bureau
Novo Nordisk files 14 new lawsuits against unapproved semaglutide drugs
By IPP Bureau - August 06, 2025
These filings come after FDA issued its latest warning to patients and healthcare professionals about the serious dangers of compounded GLP-1 drugs
Vertex faces regulatory delays for Journavx and reports VX-993 Phase 2 trial failure
By IPP Bureau - August 06, 2025
Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint
Aster DM Healthcare to build Rs. 580 crore crore hospital in Bengaluru
By IPP Bureau - August 05, 2025
This will be Aster’s fifth hospital in Bengaluru
Sanofi Consumer Healthcare India reports Q2 2025 PAT at Rs. 60.7 Cr
By IPP Bureau - August 05, 2025
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
Eli Lilly inaugurates global capability centre in hyderabad to advance AI initiatives
By IPP Bureau - August 05, 2025
The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery
Strides Pharma Science report Q1 FY26 PAT at Rs. 105.6 Cr
By IPP Bureau - August 05, 2025
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
Hexaware Technologies appoints Shantanu Baruah as President & Global Head – Healthcare, Life Sciences, and Insurance
By IPP Bureau - August 04, 2025
Baruah will lead strategy, growth, and transformation across the HLS vertical, focusing on expanding digital health capabilities and accelerating AI adoption
Sanofi’s GPRC5D monoclonal antibody earns ODD in US for multiple myeloma
By IPP Bureau - August 03, 2025
Beta-HPV can directly cause skin cancer in immunocompromised people
By IPP Bureau - August 03, 2025
cSCC is one of the most common cancers in the U.S. and globally
Illumina launches new assay for tumor profiling
By IPP Bureau - August 03, 2025
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
Cellipont and CellVax expand partnership to advance manufacturing of immunotherapy for GI cancers
By IPP Bureau - August 03, 2025
The expanded partnership includes cGMP manufacturing, technology transfer for both drug substance and product
Sandoz to acquire Just–Evotec Biologics facility for $300 million
By IPP Bureau - August 03, 2025
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
NIH develops AI agent to improve accuracy of gene set analysis
By IPP Bureau - August 03, 2025
The system, called GeneAgent, cross-checks its own initial predictions for accuracy against information from established, expert-curated databases
FDA restrict 7-OH opioid products to protect consumers
By IPP Bureau - August 03, 2025
7-OH is a concentrated byproduct of the kratom plant and has shown potential for abuse by binding to opioid receptors
Johnson & Johnson submits additional data to FDA on psoriatic arthritis
By IPP Bureau - August 03, 2025
The submission is supported by results from the Phase 3b APEX study
